Skip to main
MEDP
MEDP logo

Medpace Holdings (MEDP) Stock Forecast & Price Target

Medpace Holdings (MEDP) Analyst Ratings

Based on 16 analyst ratings
Hold
Strong Buy 13%
Buy 19%
Hold 69%
Sell 0%
Strong Sell 0%

Bulls say

Medpace Holdings is projected to experience approximately 21% bookings growth in 2025, reflecting a shift towards more consistent revenue growth, bolstered by strong RFP volume and improved win rates. Despite a reduction in 2024 sales guidance, the company has raised its EBITDA outlook and EPS targets, indicating improved financial performance metrics with adjusted EBITDA significantly outperforming expectations. Operational efficiencies related to hiring and technology are anticipated to support margins, reinforcing a robust business environment conducive to revenue acceleration.

Bears say

Medpace Holdings has demonstrated a concerning trend following a significant bookings miss in the second quarter, with revenue falling short of expectations at $533 million compared to an estimate of $542 million. The company reported net new business awards of $534 million, which was well below the anticipated $596 million, resulting in a disappointing net book-to-bill ratio of 1.00 times for the quarter. Furthermore, ongoing constraints in biotech funding may lead to elevated cancellation rates, prompting a reduction in revenue forecasts for both 2024 and 2025 by $32 million and $135 million, respectively.

Medpace Holdings (MEDP) has been analyzed by 16 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 19% recommend Buy, 69% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medpace Holdings (MEDP) Forecast

Analysts have given Medpace Holdings (MEDP) a Hold based on their latest research and market trends.

According to 16 analysts, Medpace Holdings (MEDP) has a Hold consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $262, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $262, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medpace Holdings (MEDP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.